EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and ...

A team led by researchers from the National Center for Tumor Diseases (NCT/UCC) Dresden at the Carl Gustav Carus University Hospital (UKD) and the Carl Gustav Carus Faculty of Medicine at the TUD ...

Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Cullinan ...

Issued on behalf of GT Biopharma, Inc.Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash ...

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following ...

In this JCO Article Insights episode, Dr. Ece Cal interviews Dr. Martin Wermke, author of the JCO article, "Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager ...

The MarketWatch News Department was not involved in the creation of this content. SAN MATEO, Calif., March 23, 2026 /PRNewswire/ -- Kali Therapeutics, a biotechnology company focused on the discovery ...

Please provide your email address to receive an email when new articles are posted on . In this video, Philip J. Mease, MD, discusses the potential for the development of a T-cell engaging antibody.

Abpro Holdings Inc. and Celltrion Inc. have announced the submission of an IND application to the FDA for ABP-102 (CT-P72), a HER2 x CD3 T-cell engager. Pending clearance, a phase I trial in patients ...

ZURICH, Switzerland--(BUSINESS WIRE)--CDR-Life, Inc., a biotechnology company developing highly selective T cell engagers (TCEs) to treat cancer and autoimmune diseases, today announced the first ...

To permanently access this White Paper for free, fill out the short form below. T-cell engagers (TCEs) are revolutionizing cancer immunotherapy, but their discovery remains complex, requiring ...

As part of a clinical study, the Early Clinical Trial Unit (ECTU) at NCT/UCC Dresden tested the cancer immunotherapy IMA401 for the first time in patients with advanced solid tumors. IMA401 is a ...